---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091188"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2026-08-05T20:43:14+00:00"
generated_at: "2026-08-05T20:44:05.179173+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coherus Q2 2026 net loss narrows to $33.3M; LOQTORZI revenue up 37% YoY to $13.6M

## Summary
- LOQTORZI net revenue $13.6M in Q2 2026, up 37% YoY from $10.0M and 15% sequentially from $11.8M.
- GAAP net loss from continuing ops $33.3M ($0.22 diluted EPS) vs $44.9M ($0.39) in Q2 2025.
- Non-GAAP net loss $30.1M ($0.19) vs $39.0M ($0.34) in prior year; total net revenue $14.3M.
- R&D expenses fell to $21.4M from $26.3M; SG&A fell to $21.0M from $26.0M on cost reductions.
- Pipeline: tagmokitug and casdozokitug trials enrolling; initial data readouts expected 2H 2026.

## SEC filing metadata
- accession: 0001104659-26-091188
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2026-08-05T20:43:14+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/0001104659-26-091188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091188
- JSON: https://secwatch.observer/filing/0001104659-26-091188.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.